# Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC

> **NCT02568748** · PHASE3 · UNKNOWN · sponsor: **Sherief Abd-Elsalam** · enrollment: 20 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** CIK
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT02568748
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2019-06
- **Final completion:** 2019-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568748, "Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02568748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*